Edwards Lifesciences (EW) Expected to Announce Quarterly Earnings on Wednesday

Edwards Lifesciences (NYSE:EW) is expected to announce its Q2 2025 earnings results before the market opens on Wednesday, July 23rd. Analysts expect the company to announce earnings of $0.62 per share and revenue of $1.49 billion for the quarter. Edwards Lifesciences has set its FY 2025 guidance at 2.400-2.500 EPS and its Q2 2025 guidance at 0.590-0.650 EPS.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The firm had revenue of $1.41 billion for the quarter, compared to analysts’ expectations of $1.40 billion. During the same period in the prior year, the firm earned $0.66 earnings per share. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. On average, analysts expect Edwards Lifesciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $76.90 on Wednesday. Edwards Lifesciences has a 1 year low of $58.93 and a 1 year high of $89.86. The firm’s 50 day moving average is $76.40 and its 200-day moving average is $73.39. The firm has a market capitalization of $45.11 billion, a price-to-earnings ratio of 10.99, a PEG ratio of 3.93 and a beta of 1.11. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06.

Wall Street Analyst Weigh In

Several research firms have weighed in on EW. Citigroup reiterated a “buy” rating and issued a $95.00 target price (up from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a report on Tuesday. Evercore ISI increased their price objective on shares of Edwards Lifesciences from $73.00 to $77.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 8th. Dbs Bank raised shares of Edwards Lifesciences to a “hold” rating in a research report on Monday, June 2nd. Finally, Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Friday, May 16th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $80.70.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 2,570 shares of Edwards Lifesciences stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total transaction of $198,918.00. Following the transaction, the vice president owned 50,356 shares in the company, valued at approximately $3,897,554.40. The trade was a 4.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $74.40, for a total value of $837,000.00. Following the completion of the sale, the chief financial officer directly owned 41,098 shares of the company’s stock, valued at approximately $3,057,691.20. The trade was a 21.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,848 shares of company stock worth $2,314,488 in the last ninety days. Insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

A hedge fund recently bought a new stake in Edwards Lifesciences stock. Brighton Jones LLC bought a new position in Edwards Lifesciences Corporation (NYSE:EW) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,587 shares of the medical research company’s stock, valued at approximately $266,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.